Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor

NCT07358377 is registered in ClinicalTrials.gov with Atridia Pty Ltd. as lead sponsor.

NCT NCT07358377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07358377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor
Lead sponsor
Atridia Pty Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 15, 2026
Completion date
November 10, 2027
Enrollment
15 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer